This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Millikan, R. Articles by Logothetis, C. Search for Related Content PubMed PubMed Citation Articles by Millikan, R. Articles by Logothetis, C. Social Bookmarking                            What's this?

Integrated Therapy for Locally Advanced Bladder Cancer: Final Report of a Randomized Trial of Cystectomy Plus Adjuvant M-VAC Versus Cystectomy With Both Preoperative and Postoperative M-VAC

From the Center for Genitourinary Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX.

Address reprint requests to Randall E. Millikan, PhD, MD, M.D. Anderson Cancer Center, Box 013, 1515 Holcombe Blvd, Houston, TX 77030; email: rmillika{at}notes.mdacc.tmc.edu

PURPOSE: We conducted a phase III trial to investigate the timing of chemotherapy with respect to surgery for patients with resectable but high-risk urothelial cancer. The trial was also designed to evaluate the accuracy of clinical staging in patients with locally advanced cancer and the prognostic significance of chemotherapy-induced downstaging.

PATIENTS AND METHODS: A total of 140 uniformly evaluated patients with locally advanced urothelial cancer were studied. Planned treatment was five cycles of chemotherapy (M-VAC: methotrexate, vinblastine, doxorubicin, and cisplatin) plus radical cystectomy and pelvic lymph node dissection. Patients were randomly assigned to receive either two courses of neoadjuvant M-VAC followed by surgery plus three additional cycles of chemotherapy, or, alternatively, to have initial cystectomy followed by five cycles of adjuvant chemotherapy.

RESULTS: There were no significant differences in outcome between the two groups. By intent-to-treat, 81 patients (58%) remain disease-free, with median follow-up of 6.8 years. We confirmed a high rate of clinical understaging in this cohort, especially among patients showing lymphovascular invasion on biopsy. Patients with no residual muscle-invasive disease at cystectomy after neoadjuvant chemotherapy were likely to be cured.

CONCLUSION: These results lend further support to the impression from small randomized trials that, in a high-risk cohort, there is an improved cure fraction by the combination of multiagent chemotherapy and surgery, although we found no preferred sequence. Importantly, it is possible to select appropriate patients for such therapy on the basis of clinical staging information. These results establish a benchmark of outcome for this cohort.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. H.A. Hussain, D. P. Wood, D. F. Bajorin, B. H. Bochner, R. Dreicer, D. L. Lamm, M. A. O'Donnell, A. O. Siefker-Radtke, D. Theodorescu, and C. P. Dinney Bladder Cancer: Narrowing the Gap Between Evidence and Practice J. Clin. Oncol., December 1, 2009; 27(34): 5680 - 5684. [Full Text] [PDF]

				R Sawhney, D Bourgeois, and U. Chaudhary Neo-adjuvant chemotherapy for muscle-invasive bladder cancer: a look ahead Ann. Onc., September 1, 2006; 17(9): 1360 - 1369. [Abstract] [Full Text] [PDF]

				S. M. Cohen, A. Goel, J. Phillips, R. D. Ennis, and M. L. Grossbard The Role of Perioperative Chemotherapy in the Treatment of Urothelial Cancer Oncologist, June 1, 2006; 11(6): 630 - 640. [Abstract] [Full Text] [PDF]

				Y. Lotan, A. Gupta, S. F. Shariat, G. S. Palapattu, A. Vazina, P. I. Karakiewicz, P. J. Bastian, C. G. Rogers, G. Amiel, P. Perotte, et al. Lymphovascular Invasion Is Independently Associated With Overall Survival, Cause-Specific Survival, and Local and Distant Recurrence in Patients With Negative Lymph Nodes at Radical Cystectomy J. Clin. Oncol., September 20, 2005; 23(27): 6533 - 6539. [Abstract] [Full Text] [PDF]

				M. D. Galsky and H. I. Scher Bladder Cancer "Adjuvant-Lite": Tastes Great (works as well) and Less Filling (less toxic)? J. Clin. Oncol., August 1, 2005; 23(22): 4823 - 4826. [Full Text] [PDF]

				J. Lehmann, M. Retz, C. Wiemers, J. Beck, J. Thuroff, C. Weining, P. Albers, D. Frohneberg, T. Becker, P.-J. Funke, et al. Adjuvant Cisplatin Plus Methotrexate Versus Methotrexate, Vinblastine, Epirubicin, and Cisplatin in Locally Advanced Bladder Cancer: Results of a Randomized, Multicenter, Phase III Trial (AUO-AB 05/95) J. Clin. Oncol., August 1, 2005; 23(22): 4963 - 4974. [Abstract] [Full Text] [PDF]

				H. B. Grossman, R. B. Natale, C. M. Tangen, V.O. Speights, N. J. Vogelzang, D. L. Trump, R. W. d. White, M. F. Sarosdy, D. P. Wood Jr., D. Raghavan, et al. Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer N. Engl. J. Med., August 28, 2003; 349(9): 859 - 866. [Abstract] [Full Text] [PDF]

				L. C. Pagliaro, A. Keyhani, D. Williams, D. Woods, B. Liu, P. Perrotte, J. W. Slaton, J. A. Merritt, H. B. Grossman, and C. P. Dinney Repeated Intravesical Instillations of an Adenoviral Vector in Patients With Locally Advanced Bladder Cancer: A Phase I Study of p53 Gene Therapy J. Clin. Oncol., June 15, 2003; 21(12): 2247 - 2253. [Abstract] [Full Text] [PDF]

				L. C. Pagliaro, R. E. Millikan, S.-M. Tu, D. Williams, D. Daliani, C. N. Papandreou, and C. J. Logothetis Cisplatin, Gemcitabine, and Ifosfamide As Weekly Therapy: A Feasibility and Phase II Study of Salvage Treatment for Advanced Transitional-Cell Carcinoma J. Clin. Oncol., July 1, 2002; 20(13): 2965 - 2970. [Abstract] [Full Text] [PDF]

				N. J. Vogelzang Neoadjuvant MVAC: The Long and Winding Road Is Getting Shorter and Straighter J. Clin. Oncol., October 15, 2001; 19(20): 4003 - 4004. [Full Text] [PDF]